Neurology® Podcast

1. Featured Article: IgLON5 antibody: Neurological Accompaniments & Outcomes in 20 patients 2. What’s Trending: Health policy update: Coding, Reimbursement, and Quality Payment Program This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 27, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Andrew McKeon about his Neurology: Neuroimmunology & Neuroinflammation paper describing IgLON5 autoimmunity. For the “What’s Trending” segment, Dr. Jason Crowell speaks with Luana Ciccarelli and Amanda Napoles on regulatory updates in coding and reimbursement, MACRA, and tips for private practitioners on participating in the Quality Payment Program. DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. McKeon has patent applications pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; has consulted for Grifols, Medimmune, Inc., and Euroimmun (but did not receive personal compensation for these activities); and has received research support from Medimmune, Inc. and Euroimmun. Dr. Crowell reports no disclosures. Luana Ciccarelli and Amanda Napoles are employed by the American Academy of Neurology.

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know 2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists. DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know 2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists. DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know 2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists. DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know 2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists. DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Molecular Genetic Testing for Hereditary Ataxia – What Every Neurologist Should Know 2. What’s Trending: Recent changes to Maintenance of Certification Requirements This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 20, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Thomas Bird about his Neurology: Clinical Practice paper on the benefits and limitations of exome sequencing to identify hereditary ataxias. For the “What’s Trending” segment, Dr. Stacey Clardy with Dr. Laurie Gutmann about recent updates to the Maintenance of Certification requirements and tips to ease the process for neurologists. DISCLOSURES: Dr. Bird serves on the editorial board for GeneReviews.org; holds patents for genetic testing technology for CMT1C and SCA14; and has received research support from the Department of Veterans' Affairs (Merit Research Grant, PI, 2009-2017). Dr. Gutmann serves on the editorial board for Up-to-Date Online (Hypokalemic and Hyperkalemic Periodic Paralysis); and has recieved research support from Alexion Pharmaceuticals, Inc. and the NIH (U01 NS069498-01 A1, 3P50NS044283-07S1, U01 NS026835-01A1, U01 NS058728-01, and U01 NS077179-01). Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses. DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses. DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses. DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses. DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence 2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy diagnoses. DISCLOSURES: Dr. Sposato has received travel or speaker honoraria from Boehringer Ingelheim and Pfizer; serves on the Editorial Board for Neurology; and has received research support from Kathleen & Dr Henry Barnett Research Chair in Stroke Research, Boehringer Ingelheim (salary support for a fellow), Edward and Alma Saraydar Neurosciences Fund, Opportunities Fund of the Academic Health Sciences Centre Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario, and Boehringer Ingelheim. Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press, 2016); has consulted for Novartis, Bristol Meyers Squibb, and Bionest; and has received research support from Biogen (ARISE study). Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. McAllister and Dr. Zalewski report no disclosures.

This month’s Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper “Multimodal MRI markers and dementia risk in cerebral small vessel disease.” This interview first aired in the October 31, 2017 episode of the podcast.

This month’s Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper “Multimodal MRI markers and dementia risk in cerebral small vessel disease.” This interview first aired in the October 31, 2017 episode of the podcast.

This month’s Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper “Multimodal MRI markers and dementia risk in cerebral small vessel disease.” This interview first aired in the October 31, 2017 episode of the podcast.

This month’s Delayed Recall episode includes three recent interviews on the topic of cognitive impairment. In the first interview, from the January 16, 2018 episode, Dr. Jeff Burns speaks with Dr. Ronald Petersen about the recent AAN practice guideline paper on mild cognitive impairment. Next, in and interview from the January 2, 2018 podcast, Dr. Ted Burns and Dr. Damian Garde discuss recent Alzheimer disease trials; and in the third and final interview, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper “Multimodal MRI markers and dementia risk in cerebral small vessel disease.” This interview first aired in the October 31, 2017 episode of the podcast.